Opus Genetics director granted 24,367 RSUs
Graves Adrienne L reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Graves Adrienne L reported acquisition or exercise transactions in this Form 4 filing.
Opus Genetics, Inc. director Adrienne L. Graves received a grant of 24,367 shares of Common Stock in the form of restricted stock units as compensation. These units vest upon the earlier of one year from the grant date or the day before the company’s next annual stockholder meeting, subject to continued service. After this award, Graves directly holds 127,514 shares of common stock.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 24,367 | $0.00 | $0.00 |
Footnotes (1)
- F1. Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.
Key Figures
Key Terms
restricted stock units financial
annual meeting of stockholders financial
vesting date financial
grant, award, or other acquisition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Opus Genetics (IRD) report for Adrienne L. Graves?
How do the restricted stock units for Adrienne L. Graves at Opus Genetics vest?
Is the Form 4 transaction for Opus Genetics (IRD) a market buy or sale?
What does transaction code “A” mean in the Opus Genetics (IRD) Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.